FDA approves Nizoral ketoconazole for internal fungal diseases
The FDA approves the brand Nizoral for ketoconazole to treat internal fungal diseases with limited side effects. Janssen Pharmaceutica will manufacture and distribute it in New Brunswick New Jersey. Uses include histoplasmosis cocidioidomycosis candidiasis candiduria and mucocutaneous candidiasis with potential in paracoccidioidomycosis.